+1 877 302 8632
+1 888 205 9894 (Toll-free)

Protein G Sepharose Column Bead

IP, Purif Protein G Sepharose beads 90 µm
Pubmed (1)
Catalog No. ABIN412455
Plus shipping costs $45.00
1 mL ABIN412455
1 mL ABIN412455
local_shipping Shipping to: United States
Delivery in 2 to 3 Business Days
  • Target
    Immunoprecipitation (IP), Purification (Purif)
    Protein G Sepharose Column for affinity purification of antibodies.
    High binding capacity = Binding of IgG >20 mg human or rabbit IgG/ml Protein G-Sepharose.
    Minimal Leaching of the Ligand
    Flow Rate Tested* = 2.07 ml/min.
    *Test condition: = Calculations based on the time required to pass 18 ml of water through 2 ml settled beads (column diameter 1.5 cm).
    Usage = Reusable for up to 10 times without significant loss of binding capacity.
    Protein G Sepharose is prepared by covalently coupling Recombinant Protein G (contains three IgG binding domain) to 6 % crosslinkedsepharose beads. The coupling technique is optimized to give a high binding capacity for IgG. The capacity of IgG binding could be greater than 10 mg of human IgG per mL of wet bead.
    Bead Ligand
    Protein G
    Bead Matrix
    Sepharose beads
    Bead Size
    90 µm
  • Target
  • Application Notes
    - Purification of monoclonal and polyclonal antibodies from culture media, serum, ascites fluid or hybridoma supernatants.
    - Isolation of antibody/antigen complexes in immunoprecipitation experiments, since only the Fc region is involved in antibody binding and the Fab region is available for binding antigen.
    For Research Use only
  • Format
    Ready-to-use pre-packed columns of 1 ml or 5 ml bead volume in PBS with 0.02% sodium azide. 
    4 °C
    Expiry Date
    12 months
  • Traini, Piccolo, Tinari, Rossi, La Sorda, Spinella, Bagnato, Lattanzio, DEgidio, Di Risio, Tomao, Grassadonia, Piantelli, Natoli, Iacobelli: "Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody." in: Molecular cancer therapeutics, Vol. 13, Issue 4, pp. 916-25, 2014 (PubMed).

You are here:
help Support